esperion

BNET Resources

• sort by:
• Relevance
• Date
• Popularity

esperion Escapes the Pfizer Borg

Esperion Therapeutics, a biotech that Pfizer spent $1.3 billion acquiring in 2003, is free once more. And its founder, Roger Newton, is apparently putting the band back together. Newton, in fact, has just pulled off one of the rarer and most complicated moves in biotechnology -- the...

Tags: Pfizer Inc., Esperion, Biotechnology, Mergers & Acquisitions, Investment, Finance, David P. Hamilton

Blog posts 2008-05-01

Additional Resources

esperion Therapeutics Completes $22.75 M Series A Financing

Pfizer Inc Spinout of Esperion Therapeutics - Founding Team to Focus on HDL Therapies As a Private Entity ANN ARBOR, Mich. & NEW YORK -- Esperion Therapeutics, Inc. a biopharmaceutical company formed to focus on the discovery and development of compounds to treat cardiovascular and metabolic disease, today...

Articles 2008-05-01

SemBioSys Appoints Former esperion Officer to Board of Directors.

CALGARY, Canada, December 13 /PRNewswire/ -- SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that Oye Olukotun, MD, MPH, FACC, FAHA, has agreed to join the Board of Directors of...

Articles 2007-12-13

The home runs.(Avalon Investments and its investments)(Brief article)

Byline: Tom Henderson Ann Arbor-based Avalon Investments began raising $100 million and eventually invested in 24 companies. It had some failures, some modest successes and two home runs. They were: Esperion Therapeutics Avalon invested $2.5 million in Ann Arbor-...

Articles 2007-06-25

Dr. Roger Newton, Co-Discoverer of Lipitor(R), Joins Resverlogix Board of Directors

Resverlogix Corp. ("Resverlogix") (TSX: RVX) is pleased to announce today that the Board of Directors has appointed Roger Newton, PhD, to the Board effective July 10, 2007. "I am very pleased to be joining the Board of Directors of Resverlogix. It is a very exciting time for the NexVasTM Plaque...

Articles 2007-05-14

6 VC success stories.(Supplement )(venture-capital)(ArborText Inc.; esperion Therapeutics Inc.; QUATRx Pharmaceuticals Co.)

Michigan's venture-capital industry has begun to gain momentum, but success stories have been growing for years. Here are six examples of companies that turned a good idea into venture-capital success: Arbortext: The big payoff Arbortext Inc., a maker of business editing...

Articles 2007-04-23

Week In Review; From www.crainsdetroit.com, week of Dec. 2-8.(Pfizer Inc. to cut worldwide staff)(Google Inc.'s new office at Ann Arbor )(Michael Guido mayor of Dearborn dies)

Pfizer unsure of local effects of end of drug research A spokesman for Pfizer Inc. said it's unclear how the company's announcement to end research on a potential blockbuster drug would affect Michigan. The company did announce Nov. 28 that it would...

Articles 2006-12-11

Resverlogix Corp.: RVX208 Unique MOA Positions it as a Leader in ApoA-I/HDL Marketplace

Resverlogix Corp. ("Resverlogix") (TSX: RVX), announced that the Company's lead drug candidate RVX208 unique mechanism of action MOA is well positioned in the emerging HDL therapeutic market segment for reducing atherosclerosis and heart disease. Given recent events in the marketplace regarding cholesterol management drugs, Resverlogix verifies that its lead candidate...

Articles 2006-12-05

Resverlogix Corp.: RVX208 Unique MOA Positions it as a Leader in ApoA-I/HDL Marketplace; Hundreds of thousands of patients in key landmark trials demonstrate that enhanced ApoA-I significantly reduces cardiovascular disease risk.

CALGARY, ALBERTA, Dec 5, 2006 CCNMatthews via COMTEX -- Resverlogix Corp. ("Resverlogix") (TSX:RVX), announced that the Company's lead drug candidate RVX208 unique mechanism of action MOA is well positioned in the emerging HDL therapeutic market segment for reducing atherosclerosis and heart disease. Given recent events in...

Articles 2006-12-05

Calendar.(Calendar)

Tuesday Nov. 7 GLEQ/Spark Business Accelerator: Entrepreneurs' Roundtable. 6-8 p.m. Ann Arbor IT Zone. Speakers: Christine Gibbons of Sensicore, Michael Long of Velcura, Luke Pinkerton of Polytorx and Maryann Andreach of Esperion. Free. Spark Central, Ann Arbor. Contact: (734) 615-9310 or...

Articles 2006-11-06

Method of Quantifying Lipid-Rich Vacuolated Macrophages in Peripheral Blood

A-2 N. Brooks, R. Devalaraja, C. Whitinger, S. Drake. Esperion Therapeutics, Division of Pfizer Global Research and Development, Ann Arbor, MI, Peripheral blood examination from Wistar rats following treatment with agents enhancing cholesterol mobilization revealed large vacuolated mononuelear cells in toxicology studies, the goal of this study was to eharaeterize...

Articles 2006-06-01

If you seek a pleasant investment environment ... Michigan starts to show up on national investors' radar screens.(Focus)

Byline: Tom Henderson So far, it's just a trickle, but national venture-capital firms are starting to discover Michigan. "I look at Michigan as one of the relatively small handful of regions that deserves more attention than the venture-capital world gives it,''...

Articles 2006-05-15

People.(appointments)

Biotechnology Timothy Mayleben, COO, Esperion Therapeutics, elected to the board of directors of Aastrom Biosciences Inc., Ann Arbor. Construction Cassandra Newman to director of client marketing, Schonsheck Inc., Wixom, from outside sales manager, Enderle Fastening Systems, Brighton. ...

Articles 2005-08-08

Calendar.(Conferences and seminars)(Calendar)

Wednesday July 27 Michigan Leaders Read: How Esperion Used Good to Great to Drive Their Business Success. Part of the LeadersConnect Breakfast Series. 7:30-9:15 a.m. Speaker: Roger Newton, CEO and founder, Esperion Therapeutics. Ann Arbor IT Zone, 330 E. Liberty St.,...

Articles 2005-07-25

Alba Therapeutics Announces the Creation of Its Corporate Advisory Board and the Appointment of VP Intellectual Property and General Counsel

BALTIMORE -- Alba Therapeutics Corporation today announced the first appointments to its Corporate Advisory Board and also announced the appointment of Chris Jeffers, Ph.D., J.D. as General Counsel and Vice President Intellectual Property. Alba's first appointees to its Corporate Advisory Board are Tim Mayleben, MBA and Roger Newton, PhD. Dr....

Articles 2005-03-03

Pfizer profits fell in first quarter

NEW YORK -- Pfizer Inc.'s profit dropped 50 percent in the first quarter because of charges associated with acquisitions as well as a tough comparison with results a year ago that were fattened by more than $2 billion in proceeds from selling consumer lines. But the results...

Articles 2004-04-21

Pfizer tops forecasts, sees "strong platform for growth"

NEW YORK AFP — US pharmaceutical giant Pfizer, maker of blockbuster drugs like Viagra and Lipitor, reported first-quarter earnings topping most forecasts and said it sees a "strong platform for growth" in 2004. The world's largest pharmaceutical firm said its net profit amounted to 2.3 billion dollars in...

Articles 2004-04-20

BioMed Expo 2004 Honors esperion Therapeutics; Michigan Governor Granholm to Present Award at Event's Closing Reception

Business Editors/Health/Medical Writers BIOMED EXPO 2004 ANN ARBOR, Mich.--BUSINESS WIRE--April 20, 2004 Michigan Governor Jennifer Granholm will participate in the closing reception at BioMed Expo 2004 to present an honorary award to Esperion Therapeutics, a division of Pfizer Global Research and Development. The event...

Articles 2004-04-20

esperion Co-Founder Dr. Jan Johansson Joins Resverlogix as Senior Vice President of Clinical Affairs.

CALGARY, ALBERTA, Mar 25, 2004 CCNMatthews via COMTEX Resverlogix Corp. (TSX-V:RVX) today announced the appointment of Jan O. Johansson, M.D., Ph.D., as Senior Vice President of Clinical Affairs. "I'm fascinated by the opportunities provided by Resverlogix technologies in the...

Articles 2004-03-25

Biotech Buzz - The Next Buyouts?

M2 PRESSWIRE-2 March 2004-StreetInsider.com Inc.: Biotech Buzz - The Next Buyouts?C1994-2004 M2 COMMUNICATIONS LTD RDATE:03012004 StreetInsider.com's New Featured Article 'Biotech Buzz - The Next Buyouts?' 03/01/04: Schering-Plough (NYSE: SGP), Teva (Nasdaq: TEVA), Sicor (Nasdaq: SCRI), Pfizer (NYSE: PFE), Esperion (Nasdaq:...

Articles 2004-03-02